New Research on Headache Treatments, Biomarkers, and the Gut-Brain Connection to Be Featured at the American Headache Society® 68th Annual Scientific Meeting
American Headache Society is preparing to host its 68th Annual Scientific Meeting from June 4–7 at the Orlando World Center Marriott, bringing together leading neurologists, headache specialists, researchers, and healthcare professionals from around the world to discuss the latest scientific advances in headache medicine and migraine treatment. The four-day conference is expected to showcase some of the most significant developments in the field, including emerging migraine therapies, novel biomarkers, genetics research, and new insights into the gut-brain connection.
The annual meeting, which will be available both in person and through an On Demand virtual format, is designed to provide clinicians and researchers with evidence-based updates on the diagnosis, management, and treatment of migraine and other headache disorders. Organizers say the 2026 scientific program reflects the rapid pace of innovation currently shaping headache medicine, with more than 350 scientific abstracts scheduled for presentation across a wide range of topics.
According to Matthew S. Robbins, incoming President of the American Headache Society, the meeting represents a landmark moment for the field as researchers continue to uncover new therapeutic targets and deepen understanding of migraine biology.
Robbins stated that the breadth and depth of the science being presented this year highlight the remarkable momentum currently driving headache research and clinical care. He noted that the meeting will gather many of the world’s foremost headache specialists and investigators to discuss discoveries that may significantly influence future treatment approaches.
The conference’s Scientific Program Committee Co-Chairs, Mark J. Burish and Christina L. Szperka, emphasized that the meeting comes during a particularly transformative period in headache medicine. They explained that the program includes an extensive lineup of internationally recognized faculty members and speakers who will present findings on new treatment targets, disease mechanisms, biomarkers, and the evolving relationship between neurological disorders and systemic health.
Among the major themes expected to dominate discussion at the meeting is the development of a new class of migraine therapies currently undergoing clinical investigation. Researchers are continuing to explore innovative approaches beyond existing calcitonin gene-related peptide (CGRP)-targeted therapies, which have already transformed migraine prevention and acute treatment over recent years. Scientists attending the conference are expected to present preclinical and clinical data that could help shape the next generation of migraine therapeutics.
Another important area of interest involves the genetics of headache disorders, including research suggesting the possible identification of a previously unrecognized headache condition. Advances in genetic sequencing and molecular diagnostics are increasingly helping researchers better understand the biological pathways involved in migraine susceptibility, chronic headache syndromes, and treatment response variability among patients.
The scientific meeting will also examine the emerging role of glucagon-like peptide-1 (GLP-1) medications in migraine care. Originally developed for the treatment of diabetes and obesity, GLP-1 receptor agonists have recently attracted attention for their potential neurological and anti-inflammatory effects. Investigators are now studying how these medications may influence migraine frequency, severity, and associated symptoms in clinical settings. The growing interest in the intersection between metabolic health and neurological disease reflects broader trends toward multidisciplinary approaches in patient management.
The 2026 conference program features five major plenary sessions, each focused on a different frontier in headache science and clinical care.
The opening plenary session, titled “New Frontiers in Treatments,” will take place on Thursday, June 4, and will focus on promising new therapeutic targets. Leading researchers will present both preclinical and clinical findings related to emerging migraine treatments while also discussing how these therapies may eventually influence clinical decision-making and individualized patient care.
On Friday, June 5, attendees will participate in a session dedicated to sensitization and placebo mechanisms in chronic pain conditions. The session will feature keynote speaker Luana Colloca, an internationally recognized expert in placebo and nocebo research. Discussions will examine intrinsic pain modulation systems, overlapping chronic pain syndromes, and the potential clinical role of open-label placebo approaches in pain management.
A second Friday plenary session will explore auditory and vestibular hypersensitivity in headache disorders. The session, titled “The Ear: Sound and Vestibular Sensitivity,” aims to bridge translational research and clinical practice by examining sound hypersensitivity, tinnitus, vestibular dysfunction, and sensory processing abnormalities. Researchers will also discuss insights from autism-related hypersensitivity studies and their implications for both pediatric and adult headache care.
Saturday’s plenary session will focus on nausea and disorders involving the gut-brain axis, an area that has become increasingly important in migraine research. Scientists are continuing to investigate how the gut microbiome, gastrointestinal inflammation, and neurological signaling pathways may contribute to migraine pathophysiology. The session will also include updated clinical guidance related to nausea management and gastrointestinal symptoms commonly experienced by patients with migraine.
The final plenary session on Sunday, June 7, will center on biomarkers, predictive tools, and personalized medicine approaches in headache disorders. Experts will present data involving blood-based biomarkers that may help predict treatment response, as well as digital biomarkers derived from wearable technologies and patient monitoring systems. The session will conclude with discussions about artificial intelligence-assisted treatment planning and the future role of multimodal personalized care in headache medicine.
In addition to the plenary sessions, the meeting will feature multiple concurrent abstract presentations, poster sessions, and educational workshops designed to provide attendees with practical clinical insights. The scientific abstracts cover a broad range of topics including epidemiology, disease mechanisms, diagnostics, pharmacology, pediatric headache disorders, neuroimaging, and therapeutic innovations.
The conference officially begins with four pre-conference educational courses on Thursday, June 4. These sessions will cover vagus nerve anatomy and therapeutic applications, migraine patient-reported outcome measures, strategies for managing refractory headache disorders, and telehealth models for headache care delivery. The inclusion of telemedicine-focused education reflects the increasing adoption of remote neurological care models in clinical practice.
Saturday’s agenda will also include two concurrent “Hot Topics” symposia examining rapidly evolving areas in both basic science and clinical treatment safety. These sessions are expected to address emerging adverse event profiles associated with headache therapies, novel molecular targets, and translational discoveries that may soon enter clinical development.
The American Headache Society will additionally recognize outstanding scientific contributions through several awards sessions highlighting high-impact research and achievements in headache medicine. Organizers say these sessions are intended to celebrate innovation while encouraging continued advancement in the field.
Career development programming will also play an important role throughout the meeting. Dedicated mentorship roundtables and educational sessions supported by the National Institutes of Health will help support early-career clinicians and researchers pursuing specialization in medicine.
As an accredited provider through the Accreditation Council for Continuing Medical Education, the American Headache Society will offer continuing medical education credits for physicians attending the meeting. Participants may earn up to 43.50 AMA PRA Category 1 Credits through both live and recorded sessions.
The conference is also expected to attract significant media attention due to the growing prevalence of migraine and headache disorders worldwide. Migraine remains one of the leading causes of disability globally, affecting millions of individuals and imposing major personal, social, and economic burdens. As scientific understanding of these conditions continues to evolve, meetings such as the AHS Annual Scientific Meeting serve as important platforms for translating research discoveries into improved patient care.
With discussions spanning genetics, neuroscience, gastrointestinal health, digital medicine, artificial intelligence, and emerging therapeutics, the 68th Annual Scientific Meeting of the American Headache Society is positioned to highlight the future direction of medicine and reinforce the importance of multidisciplinary innovation in the management of neurological disorders.
About the American Headache Society (AHS)
The mission of the American Headache Society is to improve the care and lives of people living with disorders. The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain. Educating physicians, health professionals and the public, and encouraging scientific research are the primary functions of the Society.
